Genzyme Wins Cholesterol Drug Deal
18221
Genzyme has agreed to pay at least $325 million to win the hotly contested rights to a potentially powerful cholesterol-lowering drug.
203734
GlaxoSmithKline Plc  has signed a  drug discovery deal with U.S. biotech firm ChemoCentryx  potentially worth up to $1.5 billion in milestone payments and  research funding to the privately owned group.
451993
Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
423754
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck MRCG.DE   unveiled a $13.3-billion deal to buy Europe's top biotech firm   Serono SEO.VX, and Denmark's Nycomed won the drugs unit of   Altana ALTG.DE.
370766
Scientists have shown they can reduce cholesterol levels in mice by shutting off a disease-causing gene with a technique called RNA interference.
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
249246
Genentech and Biogen Idec's drug shows positive results against multiple sclerosis.
640929
Shares of Cambridge-based Genzyme were up slightly today on news that the drug maker won approval for a drug to treat childhood leukemia.
763508
NEW YORK DEC 29, 2004  - Genzyme Corp. announced Wednesday that the US Food and Drug Administration (FDA) has approved the nucleoside analogue clofarabine (Clolar) for the treatment of children
754072
Genzyme Corp.'s planned takeover of New York cancer drug maker Bioenvision Inc. has already hit a bump: A key Bioenvision shareholder is calling the deal a lowball offer and digging in against it.
383400
Scientists have used a genetic technique to cut cholesterol in mice in a groundbreaking way which could one day be used to treat a range of human illnesses.
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
99180
THE REGION Cambridge biotech company Dyax Corp. has agreed to end its deal with Genzyme Corp. to codevelop a drug for the rare swelling disorder hereditary angioedema. The firms were jointly testing DX-88, a small protein considered Dyax's most important potential drug. Dyax said it will receive all the assets of the joint development deal and $17 million cash. Genzyme ...
421111
Genzyme Corp.  said on Friday its osteoarthritis pain treatment Synvisc will retain a separate, higher reimbursement rate, after the U.S. government reversed its earlier decision to cut the rate, sending Genzyme shares higher.
134636
By harnessing a natural gene-silencing mechanism, scientists say they have dramatically reduced the activity of a protein linked to high cholesterol.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s